Shield Therapeutics PLC Total Voting Rights Update (9658M)
January 29 2021 - 2:00AM
UK Regulatory
TIDMSTX
RNS Number : 9658M
Shield Therapeutics PLC
29 January 2021
Shield Therapeutics plc
("Shield" or the "Group")
Total Voting Rights Update
London, UK, 29 January 2021: Shield Therapeutics plc (LSE: STX),
a commercial stage, pharmaceutical company with a focus on
addressing iron deficiency with its lead product Feraccru (R)
/Accrufer(R) (ferric maltol), confirms that in accordance with the
requirements of the FCA's Disclosure and Transparency Rule 5.6.1,
the Company's issued share capital consists of 117,620,190 ordinary
shares of 1.5p each in issue, each with equal voting rights. No
shares are held in treasury.
The above figure may also be used by shareholders as the
denominator in the calculations by which they will determine
whether they are required to notify their interest, or a change to
their interest, in the Company under the FCA's Disclosure Guidance
and Transparency Rules.
For further information please contact:
Shield Therapeutics plc www.shieldtherapeutics.com
Tim Watts, Chief Executive
Officer +44 (0)19 1511 8500
Lucy Huntington-Bailey, General
Counsel and Company Secretary +44 (0) 19 1511 8500
Nominated Advisor and Broker
Peel Hunt LLP
James Steel/Dr Christopher
Golden +44 (0)20 7418 8900
Joint Broker
finnCap Ltd
Geoff Nash/Matt Radley/Alice
Lane +44 (0)20 7220 0500
Financial PR & IR Advisor
Walbrook PR +44 (0)20 7933 8780 or shield@walbrookpr.com
+44 (0)7980 541 893 / +44 (0)7584 391
Paul McManus/Lianne Cawthorne 303
About Shield Therapeutics plc
Shield is a de-risked, specialty pharmaceutical company focused
on commercialising its lead product, Feraccru(R)/Accrufer(R), a
novel, non-salt based oral therapy for adults with iron deficiency
with or without anaemia. Feraccru(R)/Accrufer(R) has been approved
for use in the United States, European Union, UK and Switzerland
and has exclusive IP rights until the mid-2030s. Feraccru(R) is
commercialised in the UK and European Union by Norgine B.V. and the
Company is currently in the process of evaluating commercialisation
options for the US market, including the potential launch of
Accrufer (R) in the US by Shield. Shield also has an exclusive
licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd.,
for the development and commercialisation of
Feraccru(R)/Accrufer(R) in China, Hong Kong, Macau and Taiwan.
For more information, please visit www.shieldtherapeutics.com .
Follow Shield on Twitter @ShieldTx
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TVRQQLFLFFLXBBZ
(END) Dow Jones Newswires
January 29, 2021 02:00 ET (07:00 GMT)
Shield Therapeutics (LSE:STX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Shield Therapeutics (LSE:STX)
Historical Stock Chart
From Jul 2023 to Jul 2024